Leading UK clinic & telehealth provider specializing in cannabis based and dissociative anesthetic medicine seeks full sale

This is a fully licensed, CQC-registered telehealth provider offering CBPM and psychedelic prescriptions across the UK. Backed by 12+ medical professionals, proprietary tech, an EU hub, and exclusive import agreements. Medical cannabis services cover pain, ADHD, psychiatry, and more. Projected to generate £4.17M in revenue in 2025, with a full business sale including licenses, IP, and digital platforms.

• Turnkey, fully virtual, CQC-registered healthcare provider in the UK with a registered office in the Czech republic. delivering specialist medical consultations for unlicensed and licensed medicines. CBPMs can be prescribed and main areas of coverage of their associated doctors are pain, psychiatry, Rheumatolgy, ADHD,. etc. They offer professional education through secure online platforms

• Authorized to prescribe unlicensed Cannabis-Based Products for Medicinal Use (CBPMs) to patients 18+ across the UK

• Network of 12 authorized medical professionals prescribing cannabis and psychedelics for a wide range of ailments.  Strong team of specialists, GP and two prescribing nurses.

• Company has a proprietary, industry leading medical technology platform that is comprised of clinic and corporate websites, a secure patient portal, a doctor collaboration platform, a CPD-accredited education portal, and integrated online payment and booking systems

• Clinical team is comprised of leading specialists in chronic pain and mental health, with extensive experience in patient care and research, ensuring evidence-based treatments that deliver meaningful outcomes

• Provides a structured and compliant pathway for prescribing CBPMs, integrating eligibility assessments, team reviews, and follow-ups, alongside general prescribing services and physical examination referrals when necessary

• Company collaborates with licensed partners for the importation, storage, and distribution of unlicensed medicines, including CBPMs, and works with licensed distributors for dispensing both licensed and unlicensed medications

• Has access to over 28 supply partners and a lab testing partner

• The company holds an exclusive agreement with a strategic investor and major importer to bring medical cannabis into the UK under a Type 1 license. Also, agreements with two pharmacies facilitating direct-to-patient medication distribution.

• Company is projected to generate £4.17 million in revenues for the 2025 tax year

• Revenue streams come from patients, pharmacy sales, and educational services for medical professionals

• Company is structured to support and receive compensation for clinical trials, with established connections to leading universities and initial collaborations with the NHS

• In the process of applying for the NHS Services list, enabling rapid access to a new patient’s Summary Care Record, reducing wait times from weeks to minutes—a key legal step in prescribing CBPMs. Also applying for CyberEssential certification

• The company offers a complete turnkey solution for access to the UK market and a dedicated hub in Europe that could be developed to mirror the UK operation

• Company is seeking a full sale of the going concern business, licences, IP/trademarks, telehealth digital platforms and more.